Although Pfizer and AstraZeneca seem to be winning the EUA for a coronavirus vaccine, it doesn’t seem to be worrying the investors of MRNA stock. Pfizer, along with BioNTech will probably be the first drugmakers to win the EUA, with AstraZeneca putting its vaccines throughout the world more than any other brand. Despite these obvious disadvantages, investors believe the MRNA stock has three important advantages.
The MRNA stock doesn’t need to be shared
AstraZeneca as well as Pfizer would have to share their profits following a successful coronavirus vaccine. While Pfizer would have to pay almost as much as $563 million to BioNTech, AstraZeneca will have to help Oxford University. Yet, no financial details of such collaboration have come out in the open. The MRNA Stock, on the other hand, doesn’t need to be a part of any collaboration- as it owns the stocks of its vaccines alone.
Modern will Enjoy Several Platform Possibilities
If the MRNA stock is able to successfully create the mRNA-1273 vaccine, it will expand the mRNA line into a completely separate platform. There are at least 12 other mRNA vaccines for various other illnesses that would benefit from this. Pfizer, as well as AstraZeneca have nothing of that sort on hand.
The small size of the MRNA stock has actually worked in their favor as the developments that have taken place in its vaccines have led to them accruing a much greater share of profits. The large scale of Pfizer and AstraZeneca have rendered that impossible for the respective companies.
It comes as no surprise that the MRNA stock still has a lot of legroom for expansion. Sure, they will profit- but their shares won’t skyrocket- something that is going to happen to Moderna.